麻豆视频

Market Trends and Insights

Government Funding Surge Post-Pandemic

Federal investment elevated oligonucleotides to critical-infrastructure status for pandemic preparedness and precision medicine. The NIH earmarked USD 15.4 million for RNA research that improves microfluidic long-strand synthesis and nanopore sequencing, while its Technology Development Coordinating Center secures USD 1.5 million annually through 2029 to refine nucleic-acid production systems ^{[1]National Human Genome Research Institute, 鈥淩NA Technology Development Funding,鈥� genome.gov}. Parallel European grants create a trans-Atlantic push to localize supply chains, reinforce biosecurity, and accelerate oligonucleotide standards that underpin therapeutic approvals.

Clinical Adoption of Synthesized Oligos in Advanced Diagnostics

Fresh FDA guidance issued in 2024 clarifies quality requirements, accelerating diagnostic assay rollouts and boosting the oligonucleotide synthesis market ^{[2]FDA, 鈥淒rug Development Guidance for Nucleic Acid鈥揃ased Therapeutics,鈥� fda.gov}. GalNAc-conjugated antisense oligos received their first approval, confirming precise delivery chemistries that rely on high-fidelity synthesis. Personalized 鈥淣-of-1鈥� treatments now demand rapid micro-batch production, prompting service providers to integrate design-to-clinic workflows that transform how rare-disease patients are treated.

Expansion of Contract Development & Manufacturing (CDMO) Capacity

Agilent鈥檚 USD 725 million build-out, WuXi STA鈥檚 27 production lines, and MilliporeSigma鈥檚 EUR 300 million Korean facility collectively double global therapeutic output, signalling how CDMOs anchor the oligonucleotide synthesis market. Outsourced operations supply GMP-grade strands faster than in-house teams can qualify equipment, positioning CDMOs as strategic allies for drug sponsors racing toward commercialization.

Patent Cliffs Driving Next-Gen Antisense/RNA Therapies

The expiry of foundational antisense patents invites new entrants, while high-profile CRISPR disputes exemplified by Broad Institute vs. CVC reshape licensing flows without dimming investor enthusiasm. Recent rulings that invalidated select guide-RNA claims open freedom-to-operate for smaller firms, lifting barriers that once limited oligonucleotide portfolios.

Enzymatic, Benchtop 鈥淒NA Printer鈥� Launch Pipelines

DNA Script鈥檚 SYNTAX, Ansa鈥檚 1,005-base record, and Telesis Bio鈥檚 Gibson SOLA highlight how template-free polymerases deliver longer strands with fewer toxic reagents, aligning production with rising sustainability mandates. Wider availability sparks biosecurity reviews, leading to new sequence-screening frameworks that balance open innovation against dual-use risks.

Persistent High Purification & QC Costs

Therapeutic-grade purification can consume 60-70% of manufacturing budgets as high-performance liquid chromatography remains the standard for removing truncated strands and reactive impurities. Yield erosion, demonstrated by 30-mer sequences falling to 55% at 98% coupling efficiency, forces over-production that inflates reagent use and waste disposal, stressing smaller players that lack economies of scale.

IP Disputes Around CRISPR / Gene-Editing Sequences

Overlapping patent claims create legal landmines where a single guide RNA may trigger multiple licenses, driving up costs and delaying launches. Although some patents were invalidated in 2024, ongoing appeals sustain uncertainty, prompting conservative sequence designs that narrow the addressable therapeutic space.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Oligonucleotide Synthesis Market Segment Analysis

Services generated 41.02% of overall 2025 revenue as pharmaceutical sponsors prioritized turnkey solutions that compress development timelines. This dominance confirms the oligonucleotide synthesis market preference for external capacity that bundles synthesis, purification, and regulatory support into single-vendor contracts. The model suits high-value clinical batches where each lot must pass stringent GMP audits. Reagent consumption scales in parallel, offering steady annuity streams for consumables providers even as benchtop enzymatic platforms appear. 

Looking ahead, service revenue is expected to outpace product sales because compliance complexity continues to rise. CDMOs spread analytical costs across dozens of clients, whereas individual biotechs seldom justify multi-million-dollar cleanroom investments. Equipment suppliers respond with higher-throughput instruments such as 384-well synthesizers that cut per-oligo costs, yet most machines will still land inside service facilities rather than drug-maker labs. The oligonucleotide synthesis market size expansion therefore tracks CDMO build-outs, while specialized benchtop systems address niche rapid-turnaround needs within research cores.

DNA retained 43.12% command of the oligonucleotide synthesis market in 2025 thanks to mature phosphoramidite protocols that deliver >99% coupling efficiency for strands up to 120 bases. RNA鈥檚 13.95% share is set to climb as mRNA vaccines, CRISPR guides, and siRNA drugs gain clinical traction. Enzymatic synthesis favors RNA because aqueous enzymology avoids the acidic deprotection steps that degrade 2'-hydroxyl groups, extending feasible lengths beyond 200 bases without capping agents. 

Modified backbones such as phosphorothioates and 2'-O-methyl riboses already dominate antisense and RNAi therapeutics, commanding multiples of DNA鈥檚 price per base. Niche chemistries (LNA, PNA, Morpholino) occupy small slices yet supply indispensable tools for stability-critical indications. As therapeutic demand intensifies, production shifts toward GMP-compliant enzymes and greener solvents, lifting the oligonucleotide synthesis market share of RNA while DNA remains foundational for gene-assembly and PCR primer volumes.

Research retained 52.78% of 2025 activity, but therapeutics, with 14.69%, drive the lion鈥檚 share of profit as each clinical oligo can bill at 10- to 20-fold the price of a laboratory primer. Twenty-two approved nucleic-acid medicines by 2023 validated the modality, while four 2024 approvals confirm a steady pipeline. Companion diagnostics marry drug and test, doubling sequence orders per indication and tightening links between therapeutic and diagnostic markets. 

From 2025 onward, therapeutic CAGR is positioned to outrun research volumes. Patent expiries on first-generation antisense constructs open room for rare-disease developers, and venture funding flows into start-ups crafting personalized oligos. Consequently, the oligonucleotide synthesis market size attached to therapeutics will expand faster than any other segment, even if absolute unit counts stay below research quantities.

Academic institutions drove 72.32% of sequences in 2025, underlining how discovery science still underpins oligonucleotide demand. University labs churn through primers and probes for CRISPR screens, transcriptomics, and synthetic biology. Yet revenue skews toward pharmaceutical and biotechnology companies, which represented only 14.35% of volume but booked the majority of dollar value through GMP projects. 

Hospitals and diagnostic labs are the fastest-growing cohort as genetic tests migrate from central reference labs to point-of-care settings. This wave feeds the oligonucleotide synthesis market with medium-scale orders demanding medical-grade quality but not full GMP rigor, carving out a mid-tier service niche. As precision-medicine trials proliferate, academic鈥搃ndustry collaborations will deepen, funneling grant-backed discoveries into clinical pipelines that rely on CDMO strength.

Geography Analysis

North America Oligonucleotide Synthesis Market

North America captured 42.55% share in 2025, propelled by FDA guidance that de-risks development and by NIH funding that subsidizes platform innovation. United States-based firms leverage integrated ecosystems spanning venture capital, academic excellence, and manufacturing know-how. Canada benefits from proximity, with emerging GMP suites attracting cross-border projects. Mexico鈥檚 low-cost sites are beginning to draw reagent packaging and QC functions, though synthesis remains concentrated further north.

APAC Oligonucleotide Synthesis Market

Asia-Pacific held 14.78% yet registers the highest growth trajectory. Chinese sponsors poured more than USD 4 billion into small-nucleic-acid ventures during 2024, while provincial governments fast-tracked plant permits to localize supply. South Korea secured EUR 300 million from MilliporeSigma for a duplex biologics campus, and Singapore鈥檚 regulatory certainty lured multi-line expansions from WuXi STA and GenScript. India鈥檚 鈥淢ake in India鈥� drive birthed CoDx-CoSara鈥檚 new Gujarat facility, signaling regional intent to rise up the value chain.

Europe, LATAM and GCC Oligonucleotide Synthesis Market

Europe remains an innovation powerhouse but encounters PFAS-related chemical restrictions that complicate legacy phosphoramidite workstreams. Germany鈥檚 BioSpring tripled capacity and added 1,500 jobs, offsetting supply headaches by pioneering fluorine-free reagents. The United Kingdom鈥檚 Catapult centers pair public grants with biotech spin-outs, while France cultivates enzymatic start-ups. Elsewhere, Brazil and Argentina lead Latin American uptake of genetic therapies, and Gulf states build precision-medicine hubs anchored by imported oligonucleotides, foreshadowing localized production over the next decade.

Regulatory Landscape

In the United States, federal policy is tightening biosecurity controls around synthetic nucleic acids via the White House Office of Science and Technology Policy (OSTP) Nucleic Acid Synthesis Screening Framework. For federally funded life-sciences procurement, requirements tied to the framework apply from April 26, 2025. This shifts sourcing decisions for buyers of synthetic nucleic acids and benchtop nucleic acid synthesis equipment toward providers and manufacturers that implement sequence screening practices aligned with the framework.

The framework also sets stepped technical thresholds that affect how suppliers design screening and compliance workflows. A key milestone is October 13, 2026, when the screening window standard decreases to 50 nucleotides and benchtop nucleic acid synthesis equipment manufacturers must integrate capability to screen sequences for sequences of concern. In Europe, the European Medicines Agency (EMA) moved to formalize expectations through its draft Guideline on the Development and Manufacture of Oligonucleotides (EMA/CHMP/CVMP/QWP/262313/2024), with the consultation phase concluding in early 2025. This adds momentum around clearer CMC and analytical-control expectations for therapeutic-grade oligonucleotides.

Value Chain Analysis

The oligonucleotide synthesis value chain starts with upstream suppliers of nucleoside building blocks and specialty inputs (phosphoramidites for solid-phase synthesis and enzymes/nucleoside precursors for enzymatic routes), along with solvents and process reagents. It then moves through synthesis platform providers (instruments, software, and workflow consumables), CDMOs that perform GMP synthesis, purification, and analytical characterization, and finally to end users across academic research, diagnostics, and biopharma sponsors. The services layer is central because it bundles synthesis, purification, and QC into audit-ready packages, aligning with the market shift toward outsourced clinical-grade production.

Operational bottlenecks concentrate in manufacturing scale-up and downstream processing. High process mass intensity, reported at roughly 1,500 kg of solvent per 1 kg of product, makes solvent availability (notably acetonitrile) a supply-chain risk. Energy-intensive steps such as lyophilization and specialized chromatography capacity also introduce constraints. To reduce cost, waste, and cycle time, the chain is incorporating partnerships that connect novel chemistries and enzymatic platforms into established CDMO workflows, including Codexis and Axolabs (LGC Group) evaluating the ECO Synthesis platform for scalable RNA therapeutics (January 2026), and Luxna Biotech extending its partnership with BioSpring to manufacture oligonucleotides incorporating GuNA amidites (June 2026).

Market Opportunities and Future Outlook

Commercial whitespace is expanding around integrated, therapeutic-grade supply models that shorten handoffs between development, GMP API production, and specialized analytics for next-generation oligonucleotide modalities. CDMOs are putting visible capacity and service-matrix structures in place, including Asymchem unveiling an integrated TIDES commercial supply matrix at its TJ4 site in Tianjin (April 2026), with stated oligonucleotide capacity of 180 mol/year. Sponsor-side demand signals also support large-batch readiness, with ST Pharm signing a KRW 89.7 billion oligonucleotide API supply contract in March 2026, which points to API-scale supply agreements becoming more repeatable.

Opportunities also sit in higher-complexity formats and workflow specialization, including oncology-adjacent applications that require higher-throughput, high-quality oligonucleotides (for example, MRD workflows). Integrated DNA Technologies completed an expansion of its Coralville, Iowa manufacturing facility in April 2026, reporting more than a threefold increase in synthesis capacity aimed at MRD and oncology-focused oligonucleotides. This supports demand for adjacent capabilities in purification, analytics, and modified-oligo inputs. On the technology front, enzymatic and one-pot methods are moving into evaluations for commercial manufacturing, such as Axolabs evaluating Codexis ECO Synthesis (January 2026). At the same time, biosecurity compliance requirements under the U.S. OSTP screening framework create an additional opportunity layer for screening-enabled software, instrumentation, and compliant-provider networks for both service providers and benchtop equipment manufacturers.